CELCUITY LLC
NASDAQ: CELC (Celcuity Inc.)
Last update: yesterday, 5:40PM102.25
-0.36 (-0.35%)
| Previous Close | 102.61 |
| Open | 102.07 |
| Volume | 344,204 |
| Avg. Volume (3M) | 1,124,685 |
| Market Cap | 4,731,236,352 |
| Price / Book | 40.01 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2025 |
| Diluted EPS (TTM) | -3.05 |
| Total Debt/Equity (MRQ) | 113.89% |
| Current Ratio (MRQ) | 6.61 |
| Operating Cash Flow (TTM) | -102.25 M |
| Levered Free Cash Flow (TTM) | -62.83 M |
| Return on Assets (TTM) | -39.04% |
| Return on Equity (TTM) | -115.39% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Celcuity Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.5 |
| Average | 0.38 |
|
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company’s lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 13.21% |
| % Held by Institutions | 81.78% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Sio Capital Management, Llc | 30 Sep 2025 | 786,526 |
| Apis Capital Advisors, Llc | 30 Sep 2025 | 776,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 134.00 (Jefferies, 31.05%) | Buy |
| Median | 110.00 (7.58%) | |
| Low | 70.00 (Needham, -31.54%) | Buy |
| Average | 108.14 (5.76%) | |
| Total | 6 Buy, 1 Hold | |
| Avg. Price @ Call | 89.88 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wells Fargo | 12 Dec 2025 | 126.00 (23.23%) | Buy | 105.25 |
| Jefferies | 02 Dec 2025 | 134.00 (31.05%) | Buy | 97.50 |
| Wolfe Research | 18 Nov 2025 | 110.00 (7.58%) | Buy | 91.60 |
| HC Wainwright & Co. | 17 Nov 2025 | 94.00 (-8.07%) | Hold | 92.23 |
| 22 Oct 2025 | 77.00 (-24.69%) | Buy | 70.04 | |
| Craig-Hallum | 13 Nov 2025 | 108.00 (5.62%) | Buy | 86.00 |
| Stifel | 13 Nov 2025 | 115.00 (12.47%) | Buy | 86.00 |
| Needham | 20 Oct 2025 | 70.00 (-31.54%) | Buy | 70.58 |
| 03 Oct 2025 | 70.00 (-31.54%) | Buy | 50.51 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |